ASND ASND
Company Profile ↓Company Overview
ASND (ASND) is a publicly traded company listed on with a market capitalization of $15.13B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 140.1%, reflecting efficient use of shareholder capital.
Revenue has grown at a 141.4% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $720.13M (+98.0% YoY); net profit $-228.03M.
- Trailing 12 Months Year-on-year growth — revenue +98.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 141.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 141.43% |
| 1 Year: | 98.03% |
Stock Price Performance
| 1 Year: | +32.61% |
| 6 Months: | +8.69% |
| 3 Months: | +8.40% |
| 1 Month: | -8.53% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)40.96 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 140.1%.
- Compounding revenue at 141.4% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 100.95M | 158.04M | 213.63M | 247.50M | 246.60M |
| Cost of Revenue | - | 17.52M | 31.45M | 22.35M | 23.60M | 17.52M |
| Gross Profit | - | 83.44M | 126.60M | 191.28M | 223.90M | 229.09M |
| Operating Expenses | - | 187.65M | 179.55M | 180.28M | 217.46M | 204.27M |
| Operating Income | - | -104.21M | -52.95M | 11.00M | 6.44M | 24.81M |
| EBITDA | - | -44.23M | 2.32M | -33.63M | -1.34M | 23.30M |
| Interest Expense | - | 44.79M | 33.02M | 19.72M | 20.54M | 67.25M |
| Pretax Income | - | -93.56M | -35.01M | -57.37M | -26.70M | -48.18M |
| Tax Provision | - | 1.06M | 3.85M | 3.62M | 6.86M | -677.52M |
| Net Income | - | -94.63M | -38.85M | -60.99M | -33.56M | 629.34M |
| Diluted EPS | - | -1.58 | -0.82 | -1.00 | -0.55 | 9.75 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 51.17M | 266.72M | 363.64M | 720.13M |
| Cost of Revenue | 12.14M | 44.40M | 44.26M | 94.92M |
| Gross Profit | 39.04M | 222.32M | 319.38M | 625.22M |
| Operating Expenses | 600.85M | 677.86M | 598.15M | 761.49M |
| Operating Income | -561.81M | -455.54M | -278.76M | -136.27M |
| EBITDA | -529.18M | -411.17M | -290.02M | -114.31M |
| Interest Expense | 30.68M | 44.06M | 65.50M | 80.65M |
| Pretax Income | -577.82M | -474.14M | -373.24M | -212.65M |
| Tax Provision | 5.38M | 7.30M | 4.84M | 15.38M |
| Net Income | -583.19M | -481.45M | -378.08M | -228.03M |
| Diluted EPS | -10.40 | -8.55 | -6.53 | -3.76 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 1.09B | 825.59M | 1.18B | 1.30B |
| Current Assets | - | 923.47M | 702.72M | 1.06B | 1.11B |
| Cash & Equivalents | - | 444.77M | 392.16M | 559.54M | 616.04M |
| Inventory | - | 130.67M | 208.93M | 295.61M | 301.53M |
| Receivables | - | 11.91M | 35.87M | 166.28M | 141.33M |
| Total Liabilities | - | 826.39M | 971.28M | 1.29B | 1.47B |
| Current Liabilities | - | 716.78M | 736.51M | 907.86M | 1.07B |
| Long Term Debt | - | 95.40M | 223.00M | 365.08M | 385.25M |
| Total Debt | - | 508.38M | 644.26M | 856.62M | 871.79M |
| Total Equity | - | 263.35M | -145.70M | -105.71M | -162.82M |
| Shares Outstanding | - | 58.27M | 57.71M | 60.69M | 61.98M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -495.70M | -467.36M | -306.20M | 53.90M |
| Investing Cash Flow | - | 61.73M | 286.47M | 6.88M | -8.48M |
| Financing Cash Flow | - | 396.77M | 134.29M | 443.93M | 36.33M |
| Capital Expenditure | - | -14.49M | -2.44M | -1.43M | -8.48M |
| Free Cash Flow | - | -510.19M | -469.80M | -307.62M | 45.41M |
| Net Change in Cash | - | -37.19M | -46.59M | 144.61M | 81.74M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 76.3% | 83.4% | 87.8% | 86.8% |
| Operating Margin % | -1,097.9% | -170.8% | -76.7% | -18.9% |
| Net Margin % | -1,139.6% | -180.5% | -104.0% | -31.7% |
| ROE % | -221.5% | 330.4% | 357.7% | 140.1% |
| ROCE % | -150.6% | -511.4% | -102.6% | -58.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ASND
Ascendis Pharma (ASND) Stock Looks Above Fair Value As Shares Jump 24% - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOb3dUUWhIY2UzN2hhNkQ1cmx0d1VGTmpfWGJJemVBd0loUnByUUJReENvTU1lU0p1T2pmcFE1S0RhblNaVTZJWDFZWTZBQldkVXYzZ3FPS3FqalZ1Um0ta0d4UTRjVzJLX2NjUkYxSk1yRU5hNzJOM0ZtT3U1dm9RdzREbHJYVHNzaExmMH…
Ascendis Pharma to transition to direct ordinary share listing on Nasdaq - Investing.com
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQTnM5THZrTDFfVjhoS0xSVkFaQWRtYlNldGV3OXM4ZXJYaWFTdkF3Z0gwVWJ6X09TaHRDVzlGdEY4anFiTnZTckU3UzJoUWpxbFI0MWdkQTB6OGdFTjJNc1lBX1pUUzctWFJQbGdtSzZycXo4amp0ODczbWpuVWphODFMSGRKLVB2NXdERX…
ASND News & Events - Intellectia AI
<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTFBWTS1fdW5UV2VISHp3aDVacjRlaHBrYl9TSVltWDFPcmVMZnVma3ZJbDRKSVZ4alpOdERrbUJVdk01aUNlTEhjQ1FHQk9yM3BlTnRj?oc=5" target="_blank">ASND News & Events</a> <font color="#6f6f6f"…
Price to book forward of Ascendis Pharma A/S – NASDAQ:ASND - TradingView
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPcEN0czJkcGxkZFNUSVNhQmZlM0lDUi13RHlRVnN5NzVhVzNPMUZCUkVsR2lrQWpaZVF4RTIwR0pfSUZhOVJkTXBRbUx2V0tJTU9wMTdONTEybGE1UjRheVdGSl9CMDhnN3I3YjB5c2M4TzAyN3h1OUdpTVdiMHhyQTMxT2QxOGFMX1FLVm…
Ascendis Pharma A/S (ASND) Stock Analysis: Strong Buy Ratings Signal a Promising 20.23% Upside - DirectorsTalk Interviews
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxPN19oZU5PRlQ3YmktN3l1aEVvaE9sdGxCNk9fVHZSU0I0cXJDN1JjaFZUNWM4bUNoZjJNQlNjMEN2M2YyaERGUWFqMFNSZzN5clRxQS0yQk1sVnRFMHB1QXBwRlFFSlpKZE5Qc1NPTjE1YmNfUENnbE9PLTg5RmdLSUFvOHkwZUpYX2tZel…
Ascendis Pharma slides as investors digest share-structure switch and convertible-note redemption - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxQaW9YX0Y1ZzZzMjM0dFp4T2ZkZEU1WkJYODNKZ0poaHlpY0NhakNJdDlUdnB1YzY0RGx1WVM4MlBuazU5aWFvZ3RXOGllVW41ZkVZT3N0S3g4RElONUlTREVYbmJRSGVVWktieWV1U05xUXRkWWU1YXNNOG0teVN1SHZlVkRJQnRsY010al…
ASND — Frequently Asked Questions
What is the current share price of ASND?
As of 2026-08-05 17:25 PDT, ASND trades at $244.20 on NASDAQ/NYSE. Its 52-week range is $182.60 to $277.18.
What is the market capitalisation of ASND?
ASND has a market capitalisation of $15.13B on NASDAQ/NYSE.
What is the P/E ratio of ASND?
ASND trades at a trailing price-to-earnings (P/E) ratio of -64.95. Its price-to-book (P/B) ratio is -92.95.
What is the return on equity (ROE) of ASND?
ASND has a return on equity (ROE) of 140.05%. Its return on capital employed (ROCE) is -58.44%.
Is ASND a good stock to buy?
This page provides a data-driven analysis of ASND, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.